PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8697051-7	1995	The relative order of affinity of the various fat cell ARs for the physiological amines defined in binding studies and in vitro assays is alpha 2 > beta 1 > or = beta 2 > beta 3 for norepinephrine and alpha 2 > beta 2 > beta 1 > beta 3 for epinephrine.	Norepinephrine	191-205	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	168-174	
8817480-8	1996	The noradrenaline enhancement of creatine accumulation at 48 h was inhibited by the mixed alpha- and beta-antagonist labetalol and by the beta-antagonist propranolol, but was unaffected by the alpha 2 antagonist phentolamine; greater inhibition was caused by the beta 2 antagonist butoxamine than the beta 1 antagonist atenolol.	Norepinephrine	4-17	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	263-269	
7791817-9	1995	Sympathetic activity in the forearm was greater in blacks than in whites, but isoproterenol-stimulated presynaptic beta 2-adrenergic responses (which facilitated norepinephrine release) did not differ significantly between blacks and whites.	Norepinephrine	162-176	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	115-121	
7628838-1	1995	Catecholamines (adrenaline and noradrenaline) stimulate adipocyte lipolysis via three beta-adrenoceptor subtypes beta 1, beta 2 and beta 3.	Norepinephrine	31-44	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	121-138	
8098163-1	1993	Acute treatment with the beta-2 adrenergic agonist zinterol increased norepinephrine (NE) turnover in cerebral cortex and hypothalamus as measured by the rate of disappearance of NE after treatment with alpha-methyl-p-tyrosine.	Norepinephrine	70-84	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	25-31	
8258340-8	1993	In line with the lower affinity for beta 2-adrenergic receptors, norepinephrine was less effective than EPI in inducing detachment of NK cells from EC.	Norepinephrine	65-79	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	36-42	
1320047-2	1992	The lipolytic sensitivity of the nonselective beta-agonists epinephrine and isoprenaline as well as the selective agonists norepinephrine (beta 1) and terbutaline (beta 2) was significantly increased 5-10 times in omental fat cells.	Norepinephrine	123-137	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	164-170	
1653068-5	1991	Catecholamines inhibited this process with an order of potency: isoprenaline greater than adrenaline greater than noradrenaline indicating involvement of beta 2-adrenoceptors.	Norepinephrine	114-127	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	154-160	
1681086-4	1991	Noradrenaline or isoprenaline in the absence and presence of a selective beta-2 receptor antagonist, or the selective beta-1 adrenergic agonist dobutamine, caused a 2- to 2.5-fold transient lipolytic response which also peaked at 30 min but then (within 3 hr) declined to the base-line level.	Norepinephrine	0-13	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	73-79	
1971540-5	1990	Plasma norepinephrine decreased with administration of beta 2-blockade.	Norepinephrine	7-21	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	55-61	
1971535-2	1990	(-)Norepinephrine produced stimulation predominantly through beta 1-receptors and (-)epinephrine through both beta 1- and beta 2-receptors.	Norepinephrine	3-17	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	122-128	
1971540-8	1990	Norepinephrine may be less consistently related to the blood pressure rise during flight phobia stress as shown by the decrease in plasma norepinephrine with administration of beta 2-blockade.	Norepinephrine	0-14	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	176-182	
1971540-8	1990	Norepinephrine may be less consistently related to the blood pressure rise during flight phobia stress as shown by the decrease in plasma norepinephrine with administration of beta 2-blockade.	Norepinephrine	138-152	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	176-182	
2569506-2	1989	Both cell cultures contain adenylate cyclase stimulated by catecholamines with a potency order of isoprenaline greater than adrenaline greater than salbutamol much greater than noradrenaline, which is consistent with the presence of beta 2-adrenergic receptors.	Norepinephrine	177-190	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	233-239	
25459102-1	2015	beta2-Adrenergic receptors (beta2-ARs) transduce the effects of (nor)epinephrine on a variety of cell types and act as key mediators of the body"s reaction to stress.	Norepinephrine	64-80	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-5	
25459102-1	2015	beta2-Adrenergic receptors (beta2-ARs) transduce the effects of (nor)epinephrine on a variety of cell types and act as key mediators of the body"s reaction to stress.	Norepinephrine	64-80	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	28-33	
2468921-8	1989	In human ventricular membranes xamoterol stimulated marginally the adenylate cyclase and antagonized the effects of (-)-norepinephrine with a 30-fold greater affinity for beta 1- than for beta 2-adrenoceptors.	Norepinephrine	116-134	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	188-194	
2572419-1	1989	The stimulant effects of adrenaline and noradrenaline on contractile force and adenylate cyclase, mediated through beta 1 and beta 2-adrenoceptors, are analysed in isolated atrial and ventricular myocardium of man.	Norepinephrine	40-53	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	126-132	
2572419-3	1989	Usually, both adrenaline and noradrenaline stimulated adenylate cyclase predominantly through ventricular and atrial beta 2-adrenoceptors.	Norepinephrine	29-42	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	117-123	
2572419-8	1989	Noradrenaline can increase atrial and ventricular contractile force through beta 2-adrenoceptors but only at high concentrations.	Norepinephrine	0-13	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	76-82	
2572419-10	1989	In atria from atenolol-treated patients equi-inotropic concentrations of adrenaline and noradrenaline acting through beta 2 and beta 1-adrenoceptors, respectively, cause similar increases of cyclic AMP and of cyclic AMP-dependent protein kinase activity.	Norepinephrine	88-101	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	117-148	
2887164-4	1987	The stimulatory effect of (-)-noradrenaline is antagonized by beta 1-selective metoprolol and also by beta 2-selective ICI 118,551.	Norepinephrine	26-43	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	102-108	
2851354-0	1988	Contribution of beta 1- and beta 2-adrenoceptors of human atrium and ventricle to the effects of noradrenaline and adrenaline as assessed with (-)-atenolol.	Norepinephrine	97-110	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	28-34	
3277568-8	1988	Plasma epinephrine concentrations did not change significantly, whereas plasma norepinephrine concentrations increased 2 1/2-fold, probably reflecting the effect of beta 2-agonism on norepinephrine release.	Norepinephrine	183-197	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	165-171	
2852942-3	1988	The level of circulating catecholamines (epinephrine, norepinephrine) was significantly higher in patients were severe HF, which probably caused more evident decrease in lymphocyte beta 2-adrenoceptors density in these patients.	Norepinephrine	54-68	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	181-187	
2885760-5	1987	Selective blockade of beta 2-adrenoceptors without affecting beta 1-adrenoceptors still enabled both adrenaline and noradrenaline to cause maximum possible increases of contractile force through beta 1-adrenoceptors.	Norepinephrine	116-129	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	22-28	
2886078-2	1987	We hypothesized that activation of cardiac beta 2 receptors by endogenously released epinephrine and norepinephrine during surgical stress would add to the positive chronotropic response mediated by beta 1 stimulation.	Norepinephrine	101-115	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	43-49	
2885760-7	1987	beta 2-adrenoceptors can mediate half of the maximum increase of contractile force elicited by low concentrations of adrenaline and also contribute to the increase of contractile force caused by high concentrations of noradrenaline.	Norepinephrine	218-231	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-6	
3029657-5	1987	Agonist affinities (isoproterenol greater than epinephrine much greater than norepinephrine) were consistent with a predominance of beta-2 receptors; this predominance was confirmed by competition studies with the specific beta-2 receptor antagonist ICI 118-551 (75% beta-2, 25% beta-1).	Norepinephrine	77-91	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	132-138	
3020011-2	1986	The demonstration that membrane receptors for norepinephrine are coupled in a stimulatory (beta 1, beta 2) or inhibitory (alpha 2) way via nucleotide regulatory proteins to adenylate cyclase, thus increasing or decreasing the formation of the second messenger cyclic AMP, is discussed.	Norepinephrine	46-60	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	99-105	
2829863-5	1987	Low adrenaline concentrations and high noradrenaline concentrations can increase contractile strength by up to 50% of maximum through beta 2.	Norepinephrine	39-52	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	134-140	
6137369-3	1983	Infusion of the beta-adrenoceptor agonists isoprenaline (non-selective) and salbutamol (beta 2-selective), but not prenalterol (beta 1-selective) caused dose-dependent increments in plasma noradrenaline.	Norepinephrine	189-202	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	88-94	
2999616-14	1985	(-)-Propranolol antagonized the effects of (-)-noradrenaline mediated by beta 2-adrenoceptors 2 to 3 times more potently than the effects mediated by beta 1-adrenoceptors.	Norepinephrine	43-60	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	73-79	
2908820-9	1985	ICI 118,551 and propranolol equally blocked the beta 2-receptor mediated fall in diastolic pressure and the rise in noradrenaline.	Norepinephrine	116-129	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	48-54	
6126856-3	1981	This activity was stimulated (in the presence as well as in the absence of added GTP) by D,L-isoproterenol, L-epinephrine and L-norepinephrine, the relative potency of these agonists being compatible with the existence of beta-adrenoceptors of the beta2 subtype.	Norepinephrine	126-142	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	248-253	
6301307-4	1983	Beta 1- and beta 2-responses were expressed as the increments of cyclic AMP content of 10(6) lymphocytes incubated with norepinephrine (beta 1-stimulant) and salbutamol (beta 2-stimulant).	Norepinephrine	120-134	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	12-18	
6127586-2	1982	The beta-adrenoceptors had some of the characteristics of mammalian beta 2-adrenoceptors in that (i) adrenaline was more potent than noradrenaline and (ii) the pA2 values of two selection beta-adrenoceptor antagonists, atenolol (pA2 = 5.84) and alpha-methylpropranolol (pA2 = 8.42), were close to the values reported on beta 2-adrenoceptors in mammalian tissues.	Norepinephrine	133-146	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	68-74	
6300586-4	1983	Agonist potency isoproterenol greater than epinephrine greater than norepinephrine indicated that early human placenta contains an adrenergic receptor of beta-2 subtype.	Norepinephrine	68-82	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	154-160	
26504670-2	2015	New evidence show that the stress hormone noradrenaline enhances melanoma microenvironment reactivity, mainly acting through beta3-adrenoreceptors (beta2-ARs), favoring recruitment of cancer-associated fibroblasts, M2-macrophages, bone marrow-derived precursors, These events concur in sustaining a pro-inflammatory and pro-angiogenic milieu, finally boosting melanoma malignancy.	Norepinephrine	42-55	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	148-153	
6248606-4	1980	The agonist pattern of adenylate cyclase activation suggested the presence of beta-2 adrenergic receptors, since isoproterenol with a Kact of 0.7 microM was more potent than epinephrine (Kact = 8.5 microM) or norepinephrine (Kact = 90 microM).	Norepinephrine	209-223	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	78-84	
5851-0	1976	Beta2-adrenoceptors facilitating noradrenaline secretion from human vasoconstrictor nerves.	Norepinephrine	33-46	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	0-5	
6105122-2	1980	Isoproterenol was the most potent and norepinephrine the least potent of the three stimuli, suggesting a beta 2 type of an adrenergic response.	Norepinephrine	38-52	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	105-111	
26209056-11	2015	In a multiple-regression analysis, norepinephrine (beta = 2.67, P = 0.0004) and age (beta = -0.061, P = 0.022) were associated with 1-min Pmsf.	Norepinephrine	35-49	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	51-59	
24929186-0	2014	Quercetin-3-O-glucuronide inhibits noradrenaline-promoted invasion of MDA-MB-231 human breast cancer cells by blocking beta2-adrenergic signaling.	Norepinephrine	35-48	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	119-124	
25912576-0	2015	Norepinephrine attenuates CXCR4 expression and the corresponding invasion of MDA-MB-231 breast cancer cells via beta2-adrenergic receptors.	Norepinephrine	0-14	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	112-117	
25912576-11	2015	Finally, we found the specific beta2-adrenergic antagonist, ICI 118,551, eliminated the impact of norepinephrine on CXCR4 expression.	Norepinephrine	98-112	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	31-36	
21434894-2	2011	The attenuation in noradrenaline-mediated vasoconstriction is because of enhanced beta(2)-adrenergic stimulation in women.	Norepinephrine	19-32	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	82-88	
24837703-10	2014	Considering greater affinity of arterenol for alpha1-ARs than for beta2-ARs, the previous findings could be attributable to increased engagement of beta2-ARs with the rise of arterenol concentration.	Norepinephrine	32-41	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	148-153	
24837703-10	2014	Considering greater affinity of arterenol for alpha1-ARs than for beta2-ARs, the previous findings could be attributable to increased engagement of beta2-ARs with the rise of arterenol concentration.	Norepinephrine	175-184	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	148-153	
23489141-4	2013	The effects of (-)-noradrenaline, mediated through beta1 adrenoceptors (beta2 adrenoceptors blocked with ICI118551), and (-)-adrenaline, mediated through beta2 adrenoceptors (beta1 adrenoceptors blocked with CGP20712A), were assessed in the absence and presence of PDE inhibitors.	Norepinephrine	15-32	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	154-159	
24668024-6	2014	The effects of (-)-noradrenaline, mediated through beta1-adrenoceptors (beta2-adrenoceptors blocked with ICI118551), and (-)-adrenaline, mediated through beta2-adrenoceptors (beta1-adrenoceptors blocked with CGP20712A), were assessed in the absence and presence of the PDE inhibitors.	Norepinephrine	15-32	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	72-77	
15542284-4	2004	These adrenoceptors are known to be located both pre-synaptically (alpha(2) and beta(2)) and post-synaptically (beta(1) and beta(2)), raising the possibility that their association with clinical measures in CHF could be mediated either by modulation of the cardiac response to a given level of adrenergic drive or by altering norepinephrine release from sympathetic nerve terminals.	Norepinephrine	326-340	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	80-88	
17295024-1	2007	Activation of either coexisting beta1- or beta2 -adrenoceptors with noradrenaline or adrenaline, respectively, causes maximum increases of contractility of human atrial myocardium.	Norepinephrine	68-81	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	42-47	
16225854-2	2006	METHODS: The positive inotropic effects of noradrenaline (in the presence of the beta2-selective antagonist ICI118551) and adrenaline (in the presence of the beta1-selective antagonist CGP20712), mediated through beta1- and beta2-adrenoceptors, respectively, were investigated in atrial and ventricular trabeculae.	Norepinephrine	43-56	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	81-86	
16225854-2	2006	METHODS: The positive inotropic effects of noradrenaline (in the presence of the beta2-selective antagonist ICI118551) and adrenaline (in the presence of the beta1-selective antagonist CGP20712), mediated through beta1- and beta2-adrenoceptors, respectively, were investigated in atrial and ventricular trabeculae.	Norepinephrine	43-56	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	224-229	
17994288-3	2007	We found that norepinephrine had an inhibitory function on the fMLP-promoted adhesion of neutrophil granulocytes due to a down-regulation of beta2-integrin.	Norepinephrine	14-28	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	141-146	
15956122-11	2005	The subjects carrying the beta2-polymorphisms linked to weight gain and BP elevation also have higher plasma norepinephrine levels that are present at entry before weight gain and BP elevation.	Norepinephrine	109-123	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	26-31	
15542284-4	2004	These adrenoceptors are known to be located both pre-synaptically (alpha(2) and beta(2)) and post-synaptically (beta(1) and beta(2)), raising the possibility that their association with clinical measures in CHF could be mediated either by modulation of the cardiac response to a given level of adrenergic drive or by altering norepinephrine release from sympathetic nerve terminals.	Norepinephrine	326-340	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	124-132	
10997600-2	2000	Both serotonin, acting through 5HT1B/2C receptors, and norepinephrine acting through beta2 and/or beta3 receptors reduce food intake and augment sympathetic activity.	Norepinephrine	55-69	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	85-90	
11859855-6	2002	Evidence also has been presented to indicate that nicotine acts on alpha7-nicotinic receptors located on sympathetic nerve terminals, resulting in release of norepinephrine which then diffuses to act on beta2-adrenoceptos located on the neighboring nitrergic nerve terminals to release NO and therefore vasodilation.	Norepinephrine	158-172	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	203-208	
9832123-6	1998	It is interesting that norepinephrine, which exhibited no effect on galanin mRNA expression, induced a down-regulation in the level of galanin or galanin-like product accumulated in the medium of cultured ODM-2 cells to levels even lower than those induced by beta2-adrenergic agonists.	Norepinephrine	23-37	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	260-265	
9831823-2	1999	Adrenergic agonists and antagonists showed activation and inhibition constants consistent with the presence of beta2-receptors: Ka of isoproterenol < epinephrine < norepinephrine < phenylephrine; Ki of timolol < betaxolol < celiprolol < atenolol.	Norepinephrine	170-184	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	111-116	
10573779-3	1999	There is an ongoing thoracolumbar sympathetic outflow to the lower urinary tract during filling, and noradrenaline, released from adrenergic nerves and acting through stimulation of beta-adrenoceptors (beta 2 and beta 3), may relax the bladder, due to a relative dominance of beta- over alpha-adrenoceptors in the detrusor.	Norepinephrine	101-114	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	202-219	
9205950-6	1997	Furthermore, both beta 1 and beta 2-adrenoceptors can mediate experimental arrhythmias in human cardiac preparations elicited by noradrenaline and adrenaline.	Norepinephrine	129-142	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	29-35	
9403317-4	1997	Norepinephrine and epinephrine operate through differential recruitment of alpha 2- and beta-AR subtypes on the basis of their relative affinity for the different subtypes (the relative order of affinity is alpha 2 > beta 1 > or = beta 2 > beta 3 for norepinephrine).	Norepinephrine	0-14	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	237-243	
9075465-1	1997	BACKGROUND: We have previously reported an increase in symptoms of anxiety in patients with posttraumatic stress disorder (PTSD) following administration of the beta 2-antagonist yohimbine, which stimulates brain norepinephrine release.	Norepinephrine	213-227	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	161-167